Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
KNSA Price/Volume Stats
| Current price | $30.23 | 52-week high | $30.27 |
| Prev. close | $29.52 | 52-week low | $17.38 |
| Day low | $29.38 | Volume | 993,034 |
| Day high | $30.27 | Avg. volume | 627,627 |
| 50-day MA | $24.35 | Dividend yield | N/A |
| 200-day MA | $22.92 | Market Cap | 2.21B |
KNSA Stock Price Chart Interactive Chart >
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
KNSA Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KNSA Price Returns
| 1-mo | 12.92% |
| 3-mo | 40.54% |
| 6-mo | 40.54% |
| 1-year | 54.87% |
| 3-year | 249.48% |
| 5-year | 40.28% |
| YTD | 52.83% |
| 2024 | 12.77% |
| 2023 | 17.09% |
| 2022 | 27.27% |
| 2021 | -33.39% |
| 2020 | 59.76% |